Shinobi Therapeutics, Inc.
PrivateLast Round
Grant
Aug 6, 2024
Total Funding Raised
$142.3M
Company Overview
Shinobi Therapeutics, Inc. is a biotechnology company that develops off-the-shelf, immune-evasive iPSC-derived cell therapies for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shinobi Therapeutics, Inc. Comparables
Compare Shinobi Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shoreline Biosciences | 83% | |
| Notch Therapeutics | 81% | |
| HebeCell | 79% | |
Shinobi Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 6, 2024 | ||||
| Series A Extension | Aug 6, 2024 | ||||
| Series A | Dec 12, 2023 | ||||
| Series B | Feb 21, 2022 | ||||
| Series A Extension | Oct 29, 2021 | ||||
Series A | Nov 20, 2019 |
Shinobi Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chushin Venture Capital | Series A |
| Japan Agency for Medical Research and Development | Grant |
| EQT Life Sciences | Series A |
| JIC Venture Growth Investments | Series A |
| Yosemite | Series A Extension |
| Eight Roads Ventures Japan | Series B, Series A |
| Miraidoa | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Monthly visitors grew 247% MoM, reaching 8.7K.
- Feb 24, 2025
Added Mitsubishi UFJ Capital Co.,Ltd. as a customer.
Shinobi Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |